Dashboard
High Management Efficiency with a high ROE of 17.55%
Company has a low Debt to Equity ratio (avg) at 0.22 times
With a growth in Net Profit of 66.67%, the company declared Very Positive results in Sep 26
With ROCE of 20.4, it has a Very Attractive valuation with a 3.2 Enterprise value to Capital Employed
Stock DNA
Pharmaceuticals & Biotechnology
INR 217 Cr (Micro Cap)
21.00
40
0.00%
0.26
18.45%
3.94
Total Returns (Price + Dividend) 
Latest dividend: 0.5 per share ex-dividend date: Sep-19-2025
Risk Adjusted Returns v/s 
Returns Beta
News

Sanjivani Paranteral Ltd Upgraded to Buy on Improved Technicals and Financials
Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy by MarketsMojo as of 19 Nov 2026. This upgrade reflects a comprehensive reassessment across four key parameters: quality, valuation, financial trend, and technicals. The company’s improved technical indicators, fair valuation metrics, and robust financial performance underpin this positive outlook despite some near-term challenges.
Read More
Sanjivani Paranteral Ltd Valuation Turns Very Attractive Amid Market Pressure
Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from a fair to a very attractive rating. This change reflects a significant reassessment of the company’s price attractiveness relative to its historical averages and peer group, despite recent stock price softness and sector headwinds.
Read More
Sanjivani Paranteral Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals
Sanjivani Paranteral Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 12 Nov 2026. This adjustment reflects a nuanced reassessment across four critical parameters: quality, valuation, financial trend, and technicals. Despite strong quarterly financials and operational efficiency, the stock’s technical indicators and relative valuation have prompted a more cautious stance.
Read More Announcements 
Regulation 30 For In-Principle Approval
07-Nov-2026 | Source : BSERegulation 30 for In-Principle approval
Announcement under Regulation 30 (LODR)-Investor Presentation
06-Nov-2026 | Source : BSEInvestor Presentation for the Quarter ended 30th September 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSENewspaper Publication for the financial results ended 30th September 2026
Corporate Actions 
No Upcoming Board Meetings
Sanjivani Paranteral Ltd has declared 5% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Non Institution
None
Held by 0 Schemes
Held by 0 FIIs
Ashwani Anamisharan Khemka (29.88%)
Suresh Pukhraj Jain (6.5%)
50.5%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 6.25% vs 80.47% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 66.67% vs 352.73% in Jun 2026
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is -3.41% vs 30.06% in Sep 2024
Growth in half year ended Sep 2025 is -15.96% vs 23.01% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 4.49% vs 24.99% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 1.35% vs 20.37% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -2.04% vs 28.84% in Mar 2025
YoY Growth in year ended Mar 2026 is -17.31% vs 31.12% in Mar 2025